BiomX Inc (PHGE)
0.37
-0.03
(-7.50%)
USD |
NYAM |
May 08, 16:00
0.37
0.00 (0.00%)
After-Hours: 16:06
BiomX Research and Development Expense (Quarterly): 2.675M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.675M |
| September 30, 2023 | 5.641M |
| June 30, 2023 | 3.818M |
| March 31, 2023 | 4.564M |
| December 31, 2022 | 3.195M |
| September 30, 2022 | 3.536M |
| June 30, 2022 | 4.584M |
| March 31, 2022 | 4.929M |
| Date | Value |
|---|---|
| December 31, 2021 | 6.574M |
| September 30, 2021 | 6.608M |
| June 30, 2021 | 3.824M |
| March 31, 2021 | 5.67M |
| December 31, 2020 | 6.115M |
| September 30, 2020 | 6.056M |
| June 30, 2020 | 3.717M |
| March 31, 2020 | 3.529M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.675M
Minimum
Dec 2023
6.608M
Maximum
Sep 2021
4.690M
Average
4.574M
Median
Research and Development Expense (Quarterly) Benchmarks
| Taro Pharmaceutical Industries Ltd | 13.59M |
| InspireMD Inc | 2.035M |
| Alpha Tau Medical Ltd | 7.49M |
| Pluri Inc | 2.964M |
| Holdco Nuvo Group DG Ltd | -- |